Edwards LifesciencesRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Edwards Lifesciences (EW) reported revenue of $1.74B in Q2 2026, with Transcatheter Heart Valves its largest revenue segment at 86%.
Edwards LifesciencesEdwards Lifesciences sells structural heart therapies, including SAPIEN transcatheter aortic valves, PASCAL, EVOQUE, and SAPIEN M3 mitral and tricuspid systems, plus surgical heart valves.
Edwards Lifesciences (EW) is a Health Care Equipment company. Edwards Lifesciences sells structural heart therapies, including SAPIEN transcatheter aortic valves, PASCAL, EVOQUE, and SAPIEN M3 mitral and tricuspid systems, plus surgical heart valves. It was founded in 1958, is headquartered in Irvine, California and employs about 16,000 people.
As of 2026-Q2, Edwards Lifesciences's revenue breaks down across Transcatheter Heart Valves (86%), Transcatheter Mitral & Tricuspid Therapies (14%). See the revenue-by-segment chart for the full mix.
Track Edwards Lifesciences's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.
Sterling groups Edwards Lifesciences in the Healthcare sector, alongside Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), GE HealthCare (GEHC) and Idexx Laboratories (IDXX).
If you are researching Edwards Lifesciences, also look at Abbott Laboratories (ABT), Baxter International (BAX) and Becton Dickinson (BDX). You can compare all of them side by side or browse the full Healthcare sector on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026